Testing zorevunersen for Dravet syndrome
Part of Brain & nervous system clinical trials.
This study tests an experimental drug called zorevunersen for people with Dravet syndrome. It aims to see if the drug can reduce seizures and improve safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 2 to 17 years old
- Diagnosed with Dravet syndrome (seizures starting before 13 months of age)
- Confirmed SCN1A gene mutation (pathogenic, likely pathogenic, or uncertain significance)
- At least 8 major motor seizures (like generalized tonic-clonic or tonic seizures) during a 6-week observation period
- Have tried at least 2 different seizure treatments (medications, ketogenic diet, or vagus nerve stimulation)
- Currently taking at least one anti-seizure medication and not on certain sodium channel blockers (like phenytoin, carbamazepine, lamotrigine, etc.)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called LP352 for children and adults with Dravet syndrome. It compares the study drug to a placebo (a pill with no medicine) to see if it helps reduce seizures.
This Phase 3 study tests EPX-100 (clemizole) to help reduce seizures in people with Dravet syndrome whose seizures are not fully controlled by current anti-seizure medicines. You may consider this study if your Dravet diagnosis is confirmed and your medical situation fits the specific rules about medicines and seizure causes.
This study looks at “GABA signals” in the body/brain to learn more about Dravet syndrome and how it may relate to seizures. If you have Dravet syndrome caused by a specific SCN1A gene change, you may be asked to provide genetic test results and help with study visits so researchers can compare biomarker readings.
This study follows children with Dravet syndrome caused by a specific SCN1A gene change to understand how the condition develops over time. It may help families know more about what to expect.
This study tests a new gene therapy called ION337 designed to treat Dravet syndrome, a severe childhood epilepsy caused by a SCN1A gene mutation. The therapy is given as a spinal fluid injection and aims to reduce seizures in children ages 2–12.
This early-phase study tests how safe ETX101 is and whether it can help reduce seizures in young children with Dravet syndrome caused by an SCN1A gene change. It mainly enrolls infants and children with a specific type of seizure history and genetic result.
Hear when a new Dravet Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.